Thus, our in vivo data further confirmed that VPA exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer likely via induction of miRNAs that target the erbB mRNAs. The gene discussed is EGFR; the disease is neoplasm.